Community Practice Connections™: Interpreting the Therapeutic Landscape in Multiple Sclerosis

Released On
April 30, 2019

Expires On
April 30, 2020

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


Supported by educational grants from Celgene Corporation and Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credits

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward neurologists and MS subspecialists. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with MS may also participate.

Program Overview

Community Practice Connections™: Interpreting the Therapeutic Landscape in Multiple Sclerosis consists of clinical vignettes, short video interviews of leading experts in multiple sclerosis (MS), and brief summaries of clinical data related to these issues. The video interviews address answers to questions in clinical vignettes as well as questions commonly faced in the clinical practice setting.

Benefits of participating in Community Practice Connections™: Interpreting the Therapeutic Landscape in Multiple Sclerosis  include:

  • Gain insights into important indicators of aggressive MS
  • Expand knowledge of current and emerging therapies for MS
  • Improve competence regarding the integration of newly approved therapies into the management of MS

Activity Table of Contents

  • Pretest
  • Module 1: Importance of Early Diagnosis and Effective Treatment of Aggressive MS
  • Module 2: Current and Emerging Therapies and Shared Decision Making
  • Posttest
  • Evaluation and Request for Credit

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify key indicators of MS to improve early diagnosis and initiation of treatment for MS
  • Analyze the efficacy and safety profile of disease-modifying therapies (DMTs) to develop individualized treatment plans for patients with MS
  • Apply data from recent clinical trials on the role of DMTs in the existing treatment landscape and the potential for improving outcomes
  • Apply knowledge of case-based challenges to develop data-driven treatment plans based on patient-specific needs


Bruce A. Cohen, MD (Chair)

Mellen Center for Multiple Sclerosis at the Cleveland Clinic
Cleveland, Ohio

Joseph R. Berger, MD, FACP, FAAN, FANA

Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Accreditation Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Bruce A. Cohen, MD

  • Grant/Research Support: Biogen, Genentech/Roche.
  • Consultant: Biogen, Novartis, Sanofi Genzyme, Genentech/Roche.

Joseph R. Berger, MD, FACP, FAAN, FANA

  • Grant Research Support: Biogen
  • Consultant: Alcimed, Amgen, Bayer, Biogen, Bristol-Myers Squibb, EMD Serono, Eisai, Genentech/Roche, Genzyme, Inhibikase, Johnson & Johnson, Millennium/Takeda, Novartis, Pfizer, Sanofi-Aventis, Excision Bio.

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for This Activity and Receiving Credit

  1. You will need to log in to participate in the activity.
  2. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  3. At the end of the activity, educational content/audio files will be available for your reference.
  4. In order to receive a CME/CE certificate, you must complete the activity.
  5. Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.